TTR and primary hyperoxaluria: Currently, approved siRNA drugs include Onpattro® (patisiran) for hereditary amyloid transthyretin amyloidosis [31], Givlaari® (givosiran) for acute hepatic porphyria [32], Oxlumo® (lumasiran) for primary hyperoxaluria type I [33], Leqvio® (inclisiran) for hypercholesterolemia and mixed dyslipidemia [34], Amvuttra® (vutrisiran) for hereditary transthyretin-mediated amyloidosis [35], and Rivfloza® (nedosiran) for primary hyperoxaluria [36].